LBA25 Culmerciclib plus fulvestrant as first-line treatment for HR+/HER2- advanced breast cancer: A phase III trial (CULMINATE-2)
Erwei Song(Sun Yat-sen University), Fan Feng, Jiuda Zhao(Qinghai University), Yue Yin(Northwestern Polytechnical University), Hang Su(307th Hospital of Chinese People’s Liberation Army), Yuee Teng(First Hospital of China Medical University), Chi Hao(Tianjin Medical University Cancer Institute and Hospital), Xiao Tang(Heinrich Heine University Düsseldorf), Mingyuan Li(Sun Yat-sen University), Xiaofeng Wang(Virginia Tech), Bing Zhao(Xinjiang Medical University), Xu Cao(Tianjin Medical University Cancer Institute and Hospital), Ting Sun(Shantou University), Cui‐Ying Yuan(Ningxia Medical University), X. Wang(Zhejiang Cancer Hospital), Jin‐Ji Yang(Guangdong Academy of Medical Sciences)
Cited by 2
Related Papers
Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells
|Molecular Cancer|2011|700
MiR-21 Indicates Poor Prognosis in Tongue Squamous Cell Carcinomas as an Apoptosis Inhibitor
|Clinical Cancer Research|2009|435
Up-regulation of miR-21 Mediates Resistance to Trastuzumab Therapy for Breast Cancer
|Journal of Biological Chemistry|2011|309
ESCRT-III–dependent membrane repair blocks ferroptosis
|Biochemical and Biophysical Research Communications|2019|267
miR-142-5p and miR-130a-3p are regulated by IL-4 and IL-13 and control profibrogenic macrophage program
|Nature Communications|2015|261